dc.contributor.author | Lopez, Sophie | |
dc.contributor.author | Voisset, Edwige | |
dc.contributor.author | Tisserand, Julie C | |
dc.contributor.author | Mosca, Cyndie | |
dc.contributor.author | Prebet, Thomas | |
dc.contributor.author | Santamaria, David | |
dc.contributor.author | Dubreuil, Patrice | |
dc.contributor.author | De Sepulveda, Paulo | |
dc.date.accessioned | 2019-12-23T14:10:46Z | |
dc.date.available | 2019-12-23T14:10:46Z | |
dc.date.issued | 2016-08-09 | |
dc.identifier.citation | Oncotarget. 2016;7 (32):51163-51173. | es_ES |
dc.identifier.issn | 1949-2553 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/8876 | |
dc.description.abstract | CDK4/CDK6 and RB proteins drive the progression through the G1 phase of the cell cycle. In acute myeloid leukemia (AML), the activity of the CDK/Cyclin D complex is increased. The mechanism involved is unknown, as are the respective roles played by CDK4 or CDK6 in this process. Here, we report that AML cells carrying FLT3-ITD mutations are dependent on CDK6 for cell proliferation while CDK4 is not essential. We showed that FLT3-ITD signaling is responsible for CDK6 overexpression, through a pathway involving the SRC-family kinase HCK. Accordingly, FLT3-ITD failed to transform primary hematopoietic progenitor cells from Cdk6-/- mice. Our results demonstrate that CDK6 is the primary target of CDK4/CDK6 inhibitors in FLT3-ITD positive AML. Furthermore, we delineate an essential protein kinase pathway -FLT3/HCK/CDK6- in the context of AML with FLT3-ITD mutations. | es_ES |
dc.description.sponsorship | This project was supported by La Ligue Contre le Cancer (Equipe labelisee) and a grant from the Fondation ARC pour la Recherche sur le Cancer. | es_ES |
dc.language.iso | eng | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject | AML | es_ES |
dc.subject | SRC | es_ES |
dc.subject | Oncogene | es_ES |
dc.subject | Palbociclib | es_ES |
dc.subject | Protein kinase | es_ES |
dc.subject | Signaling | es_ES |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Cell Line, Tumor | es_ES |
dc.subject.mesh | Cyclin-Dependent Kinase 6 | es_ES |
dc.subject.mesh | Gene Expression Regulation, Leukemic | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Leukemia, Myeloid, Acute | es_ES |
dc.subject.mesh | Mice | es_ES |
dc.subject.mesh | Mice, Inbred C57BL | es_ES |
dc.subject.mesh | Mice, Knockout | es_ES |
dc.subject.mesh | Mutation | es_ES |
dc.subject.mesh | Proto-Oncogene Proteins c-hck | es_ES |
dc.subject.mesh | Signal Transduction | es_ES |
dc.subject.mesh | Tandem Repeat Sequences | es_ES |
dc.subject.mesh | fms-Like Tyrosine Kinase 3 | es_ES |
dc.title | An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 27323399 | es_ES |
dc.format.volume | 7 | es_ES |
dc.format.number | 32 | es_ES |
dc.format.page | 51163-51173 | es_ES |
dc.identifier.doi | 10.18632/oncotarget.9965 | es_ES |
dc.contributor.funder | Ligue Nationale Contre le Cancer (Francia) | |
dc.contributor.funder | Fondation ARC pour la recherche sur le cancer | |
dc.identifier.e-issn | 1949-2553 | es_ES |
dc.relation.publisherversion | https://doi.org/10.18632/oncotarget.9965 | es_ES |
dc.identifier.journal | Oncotarget | es_ES |
dc.repisalud.institucion | CNIO | es_ES |
dc.repisalud.orgCNIO | CNIO::Grupos de investigación::Grupo de Oncología Experimental | es_ES |
dc.rights.accessRights | open access | es_ES |